Novel Targeted Immunotherapies in Multiple Myeloma, With a Focus on Bispecific Antibodies

Nov 10, 2022

Oncology Treatment Pathways®November 2022

Download Issue PDF

Articles in this issue

Novel Targeted Immunotherapies in Multiple Myeloma, With a Focus on Bispecific Antibodies

Novel Targeted Immunotherapies in Multiple Myeloma, With a Focus on Bispecific Antibodies

Related Videos

In this sixth episode of OncChats: Traveling Through the Lung Cancer Treatment Paradigm, Aaron Franke, MD, discusses the consideration of adverse effects related to treatment with TKIs patients in non–small cell lung cancer.

Experts in oncology

Expert in oncology

Expert in oncology

Expert in oncology

Neville E. Sanjana, PhD

Expert in oncology

Expert in oncology

Experts in oncology

Expert in oncology

Related Content

Increased Germline Testing Rates Promote Crucial Breast Cancer Care

Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC

November 18th 2021

Liquid Biopsies and NGS Stand to Revolutionize Hematologic Malignancies

February 24th 2023

Gordan on Growing the Infrastructure for In-House Genomic Testing

October 14th 2021

Biomarkers Clarify Treatment Decisions and Sequencing in Endometrial Cancer

February 9th 2023

Development of Seribantumab for NRG1+ Advanced Solid Tumors Put On Hold

February 9th 2023

Increased Germline Testing Rates Promote Crucial Breast Cancer Care

Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC

November 18th 2021

Liquid Biopsies and NGS Stand to Revolutionize Hematologic Malignancies

February 24th 2023

Gordan on Growing the Infrastructure for In-House Genomic Testing

October 14th 2021

Biomarkers Clarify Treatment Decisions and Sequencing in Endometrial Cancer

February 9th 2023

Development of Seribantumab for NRG1+ Advanced Solid Tumors Put On Hold

February 9th 2023

Increased Germline Testing Rates Promote Crucial Breast Cancer Care

Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC

November 18th 2021

Liquid Biopsies and NGS Stand to Revolutionize Hematologic Malignancies

February 24th 2023

Gordan on Growing the Infrastructure for In-House Genomic Testing

October 14th 2021

Biomarkers Clarify Treatment Decisions and Sequencing in Endometrial Cancer

February 9th 2023

Development of Seribantumab for NRG1+ Advanced Solid Tumors Put On Hold

February 9th 2023

Related Content

Susan M. Domchek, MD

Increased Germline Testing Rates Promote Crucial Breast Cancer Care

Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC

Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC

November 18th 2021

Andrew Ip, MD

Liquid Biopsies and NGS Stand to Revolutionize Hematologic Malignancies

February 24th 2023

Gordan on Growing the Infrastructure for In-House Genomic Testing

Gordan on Growing the Infrastructure for In-House Genomic Testing

October 14th 2021

Emma L. Barber, MD

Biomarkers Clarify Treatment Decisions and Sequencing in Endometrial Cancer

February 9th 2023

Joseph Ferra

Development of Seribantumab for NRG1+ Advanced Solid Tumors Put On Hold

February 9th 2023

Latest Conference Coverage

Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors

Navigating Systemic Therapy for RCC: Balancing Risk Status and Response

ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC

Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.